A Multicentre, 12-Week Study of Imidapril and Candesartan Cilexetil in??Patients with Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring

Palma-Gámiz, José L.; Pêgo, M.; Márquez, E.; Pujol, M; Oliván, J; Alegría, Eduardo; Sagastagoitia-Gorostiza, José Domingo; González-Juanàtey, José Ramón

doi:10.2165/00044011-200727060-00004

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the retrospective nature of our study, we used the retention rate and the duration of treatment as additional surrogate markers of possible tolerability problems. In clinical trials comparing the efficacy of candesartan as an antihypertensive versus other angiotensin-converting enzyme inhibitors (ACEIs) or placebo, the adverse events rate of candesartan was 11% 27 and 16.1% 28 .…”

Section: Discussionmentioning

confidence: 99%

Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study

Sánchez-Rodríguez

Sierra

Planchuelo‐Gómez

et al. 2021

Sci Rep

View full text Add to dashboard Cite

To date, two randomized, controlled studies support the use of candesartan for migraine prophylaxis but with limited external validity. We aim to evaluate the effectiveness and tolerability of candesartan in clinical practice and to explore predictors of patient response. Retrospective cohort study including all patients with migraine who received candesartan between April 2008-February 2019. The primary endpoint was the number of monthly headache days during weeks 8–12 of treatment compared to baseline. Additionally, we evaluated the frequency during weeks 20–24. We analysed the percentage of patients with 50% and 75% response rates and the retention rates after three and 6 months of treatment. 120/4121 patients were eligible, aged 45.9 [11.5]; 100 (83.3%) female. Eighty-four patients (70%) had chronic migraine and 53 (42.7%) had medication-overuse headache. The median number of prior prophylactics was 3 (Inter-quartile range 2–5). At baseline, patients had 20.5 ± 8.5 headache days per month, decreasing 4.3 ± 8.4 days by 3 months (weeks 12–16) and by 4.7 ± 8.7 days by 6 months (paired Student’s t-test, p < 0.001). The percentage of patients with a 50% response was 32.5% at 3 months and 31.7% at 6 months, while the retention rate was 85.0% and 58.3%. The number of prior treatments (Odds ratio 0.79, 95% CI 0.64–0.97) and the presence of daily headache (Odds ratio 0.39, 95% CI 0.16–0.97) were associated with a lower probability of response. Candesartan showed beneficial effects in the preventive treatment of migraine in clinical practice, including patients with chronic migraine, medication-overuse headache and resistance to prior prophylactics.

show abstract

Section: Discussionmentioning

confidence: 99%

Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study

Sánchez-Rodríguez

Sierra

Planchuelo‐Gómez

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension

et al. 2008

View full text Add to dashboard Cite

show abstract

A Multicentre, 12-Week Study of Imidapril and Candesartan Cilexetil in??Patients with Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring

Abstract: Imidapril in once-daily doses of up to 20mg was shown to be at least as effective as candesartan cilexetil given in once-daily doses of up to 16 mg in reducing BP throughout the entire 24-hour dosing interval. Both drugs were well tolerated.

Cited by 2 publications

References 17 publications

Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study

Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study

Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension

Contact Info

Product

Resources

About